Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | BDTX-4933 + Cetuximab + Fluorouracil + Leucovorin + Oxaliplatin |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| BDTX-4933 | BDTX4933|BDTX 4933 | BRAF Inhibitor 26 | BDTX-4933 inhibits BRAF mutations, including class 1, 2 and 3 mutations, and active RAF dimers, which potentially decreases tumor growth (Cancer Res 2023;83(7_Suppl):Abstract nr 3415). | |
| Cetuximab | Erbitux | IMC-C225 | EGFR Antibody 72 | Erbitux (cetuximab) is a monoclonal antibody directed against EGFR, which inhibits signal transduction and cell proliferation (PMID: 28695301). Erbitux (cetuximab) is FDA-approved for use in head and neck squamous cell carcinoma and KRAS wild-type, EGFR-positive colorectal cancer, and in combination with Braftovi (encorafenib) with or without mFOLFOX6 in patients with metastatic colorectal cancer with BRAF V600E (FDA.gov). |
| Fluorouracil | Adrucil | 5-FU|5-Fluorouracil | Chemotherapy - Antimetabolite 14 | Adrucil (fluorouracil) is an antimetabolite chemotherapeutic agent, which interferes with DNA and RNA synthesis thereby preventing cancer cell growth and is FDA approved for colorectal, breast, stomach, and pancreatic cancer (FDA.gov). |
| Leucovorin | Wellcovorin | Calcium folinate|Calcium citrovorum factor|folinic acid | Chemotherapy - Antimetabolite 14 | Wellcovorin (leucovorin) is a metabolite of folate that enhances the efficacy of fluoruracil (PMID: 32490554). |
| Oxaliplatin | Eloxatin | Diaminocyclohexane Oxalatoplatinum | Chemotherapy - Platinum 7 | Eloxatin (oxaliplatin) is comprised of a platinum complex, which causes DNA-platinum cross-links, inhibition of DNA replication and transcription, and cell toxicity, and is FDA approved for colorectal cancer (FDA.gov). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05786924 | Phase Ib/II | BDTX-4933 + Fluorouracil + Irinotecan + Leucovorin + Panitumumab BDTX-4933 + Cetuximab + Fluorouracil + Irinotecan + Leucovorin BDTX-4933 BDTX-4933 + Fluorouracil + Leucovorin + Oxaliplatin + Panitumumab BDTX-4933 + Cetuximab + Fluorouracil + Leucovorin + Oxaliplatin BDTX-4933 + Gemcitabine + Nab-paclitaxel | Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies | Recruiting | USA | 0 |